Overview

Exparel and Ankle Surgery

Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
This study involves a drug called Exparel that has been approved by the US Food and Drug Administration (FDA), for application directly to wound sites. EXPAREL® is a long acting pain reliever. It is being given in this study to see if it provides safe and effective pain relief after ankle surgery. Because it is a long acting drug, it may lessen pain relief for as much as 72 hours after surgery. EXPAREL® has not been approved by the FDA for administration by popliteal block, which is the method the study doctors will use to give the patients the drug. Giving the drug by popliteal block involves inserting a small tube in to the back of the knee to deliver the drug. The study doctors wish to determine if patients undergoing ankle surgery and receiving this drug have less pain and less need for narcotic medication.
Phase:
N/A
Details
Lead Sponsor:
Rutgers, The State University of New Jersey
Treatments:
Bupivacaine